Web based Drug Database (1.07 Linux)

NEFOPAM HYDROCHLORIDE

Names
Common Name	NEFOPAM HYDROCHLORIDE
Other Name	NEFOPAM HYDROCHLORIDE
Pharmacological Group	ANALGESICS - NON OPIOID
Chemical Name	3,4,5,6-Tetrahydro-5-methyl-1-phenyl-1H-2,5-benzoxazocine hydrochloride
Chemical Group

Attributes

Indications	Contraindications	Prescriber Cautions	Patient Cautions
Toxicity	Side Effects	Liver Disease	Renal Failure
Pregnancy	Lactation	Pharmacological Actions	Diagnostic Procedures
Drugs	Interactions

Indications

Toothache
Pain
Musculoskeletal pain
Postoperative pain

Contraindications

Epilepsy
Analgesic allergy
Progressive myoclonic epilepsy
Acute myocardial infarction
Adverse reaction to aromatic analgesics

Prescriber Cautions

Consult current official advice regarding NEFOPAM HYDROCHLORIDE
Not recommended for children
Caution in patients taking Monoamine Oxidase Inhibiting antidepressants (MAOI). NEFOPAM HYDROCHLORIDE may cause hypertensive crisis

Patient Cautions

See information on products containing NEFOPAM HYDROCHLORIDE for specific advice for patients

Toxicity

- None Listed -

Side Effects

Abdominal pain - Common
Angioneurotic oedema - Common
Confusion - Common
Convulsions - Common
Diarrhoea - Common
Dizziness - Common
Dry mouth - Common
Hallucinations - Common
Hypotension - Common
Light-headedness - Common
Nausea - Common
Nervousness - Common
Palpitations - Common
Paraesthesia - Common
Syncope - Common
Tremor - Common
Urinary retention - Common
Blurred Vision - Uncommon
Drowsiness - Uncommon
Excessive sweating - Uncommon
Headache - Uncommon
Insomnia - Uncommon
Tachycardia - Uncommon
Vomiting - Uncommon

Liver Disease

Avoid NEFOPAM HYDROCHLORIDE in severe liver disease
NEFOPAM HYDROCHLORIDE causes sodium and water retention in liver disease
NEFOPAM HYDROCHLORIDE - increased risk of gastrointestinal bleeding in liver disease

Renal Failure

Avoid NEFOPAM HYDROCHLORIDE if possible in mild renal failure
Manufacturer advises reduce dose of NEFOPAM HYDROCHLORIDE in renal failure
NEFOPAM HYDROCHLORIDE - reduces renal function in renal failure
NEFOPAM HYDROCHLORIDE - sodium and water retention in renal failure

Pregnancy

Insufficient information available about NEFOPAM HYDROCHLORIDE in pregnancy
Manufacturer advises avoid NEFOPAM HYDROCHLORIDE in the 1st, 2nd & 3rd TRIMESTER of pregnancy

Lactation

Amount of NEFOPAM HYDROCHLORIDE in breast milk too small to be harmful

Pharmacological Actions

ANALGESIC effect
SYMPATHOMIMETIC effect
ANTIMUSCARINIC effect

Diagnostic Procedures

- None Listed -

Drugs containing NEFOPAM HYDROCHLORIDE

ACUPAN 30mg tablets
NEFOPAM HCL 30mg tablets

Interacting Ingredients

AMINOPHYLLINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of AMINOPHYLLINE. Moderate risk. Avoid
AMITRIPTYLINE
Likely interaction of AMITRIPTYLINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
AMOXAPINE
Likely interaction of AMOXAPINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
BAMBUTEROL HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of BAMBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
BECLAMIDE
Infrequent reports of BECLAMIDE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
BECLOMETASONE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of BECLOMETASONE [INHALED]. Moderate risk. Avoid
BETAMETHASONE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of BETAMETHASONE [INHALED]. Moderate risk. Avoid
BISMUTH CHELATE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of BISMUTH CHELATE. Moderate risk. Avoid
BUDESONIDE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of BUDESONIDE [INHALED]. Moderate risk. Avoid
BUFYLLINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of BUFYLLINE. Moderate risk. Avoid
BUTRIPTYLINE
Likely interaction of BUTRIPTYLINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
CARBAMAZEPINE
Infrequent reports of CARBAMAZEPINE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
CARBENOXOLONE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of CARBENOXOLONE. Moderate risk. Avoid
CHOLINE THEOPHYLLINATE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of CHOLINE THEOPHYLLINATE. Moderate risk. Avoid
CIMETIDINE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of CIMETIDINE. Moderate risk. Avoid
CLOMIPRAMINE HYDROCHLORIDE
Likely interaction of CLOMIPRAMINE HYDROCHLORIDE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
CLONAZEPAM
Infrequent reports of CLONAZEPAM increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
CLOPIDOGREL
Theoretical potential for NEFOPAM HYDROCHLORIDE increasing the PLATELET ANTAGONIST effect of CLOPIDOGREL. Moderate risk. May need to avoid combination
CROMOGLICATE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of CROMOGLICATE [INHALED]. Moderate risk. Avoid
DEGLYCYRRHIZINISED LIQUORICE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of DEGLYCYRRHIZINISED LIQUORICE. Moderate risk. Avoid
DESIPRAMINE HYDROCHLORIDE
Likely interaction of DESIPRAMINE HYDROCHLORIDE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
DIPROPHYLLINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of DIPROPHYLLINE. Moderate risk. Avoid
DOSULEPIN HYDROCHLORIDE
Likely interaction of DOSULEPIN HYDROCHLORIDE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
DOXEPIN
Likely interaction of DOXEPIN increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
EPHEDRINE HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of EPHEDRINE HYDROCHLORIDE. Moderate risk. Avoid
ESOMEPRAZOLE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of ESOMEPRAZOLE. Moderate risk. Avoid
ETHOSUXIMIDE
Infrequent reports of ETHOSUXIMIDE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
FAMOTIDINE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of FAMOTIDINE. Moderate risk. Avoid
FENOTEROL HYDROBROMIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of FENOTEROL HYDROBROMIDE. Moderate risk. Avoid
FLUTICASONE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of FLUTICASONE [INHALED]. Moderate risk. Avoid
FORMOTEROL
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of FORMOTEROL. Moderate risk. Avoid
FOSPHENYTOIN
Infrequent reports of FOSPHENYTOIN increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
GABAPENTIN
Infrequent reports of GABAPENTIN increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
IMIPRAMINE
Likely interaction of IMIPRAMINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
INDACATEROL
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of INDACATEROL. Moderate risk. Avoid
IPRINDOLE
Likely interaction of IPRINDOLE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
IPRONIAZID
Theoretical potential for IPRONIAZID increasing the HYPERTENSIVE effect of NEFOPAM HYDROCHLORIDE. High risk. May need to avoid combination
ISOCARBOXAZID
Theoretical potential for ISOCARBOXAZID increasing the HYPERTENSIVE effect of NEFOPAM HYDROCHLORIDE. High risk. May need to avoid combination
ISOETARINE HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of ISOETARINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of ISOPRENALINE HYDROCHLORIDE. Moderate risk. Avoid
ISOPRENALINE SULPHATE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of ISOPRENALINE SULPHATE. Moderate risk. Avoid
KETOTIFEN
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of KETOTIFEN. Moderate risk. Avoid
LAMOTRIGINE
Infrequent reports of LAMOTRIGINE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
LANSOPRAZOLE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of LANSOPRAZOLE. Moderate risk. Avoid
LOFEPRAMINE
Likely interaction of LOFEPRAMINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
MESUXIMIDE
Infrequent reports of MESUXIMIDE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
METHYLEPHEDRINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of METHYLEPHEDRINE. Moderate risk. Avoid
METHYLPHENOBARBITAL
Infrequent reports of METHYLPHENOBARBITAL increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
MIFEPRISTONE
Theoretical potential for NEFOPAM HYDROCHLORIDE increasing the PROSTANERGIC effect of MIFEPRISTONE. Potential risk. Avoid
MOCLOBEMIDE
Theoretical potential for MOCLOBEMIDE increasing the HYPERTENSIVE effect of NEFOPAM HYDROCHLORIDE. High risk. May need to avoid combination
MONTELUKAST
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of MONTELUKAST. Moderate risk. Avoid
NEDOCROMIL SODIUM
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of NEDOCROMIL SODIUM. Moderate risk. Avoid
NIZATIDINE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of NIZATIDINE. Moderate risk. Avoid
NORTRIPTYLINE
Likely interaction of NORTRIPTYLINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
OMEPRAZOLE [ORAL]
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of OMEPRAZOLE [ORAL]. Moderate risk. Avoid
OMEPRAZOLE [PARENTERAL]
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of OMEPRAZOLE [PARENTERAL]. Moderate risk. Avoid
ORCIPRENALINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of ORCIPRENALINE. Moderate risk. Avoid
ORCIPRENALINE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of ORCIPRENALINE [INHALED]. Moderate risk. Avoid
PANTOPRAZOLE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of PANTOPRAZOLE. Moderate risk. Avoid
PHENELZINE
Theoretical potential for PHENELZINE increasing the HYPERTENSIVE effect of NEFOPAM HYDROCHLORIDE. High risk. May need to avoid combination
PHENOBARBITAL
Infrequent reports of PHENOBARBITAL increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
PHENYTOIN
Infrequent reports of PHENYTOIN increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
PHENYTOIN SODIUM
Infrequent reports of PHENYTOIN SODIUM increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
PIRBUTEROL
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of PIRBUTEROL. Moderate risk. Avoid
PRIMIDONE
Infrequent reports of PRIMIDONE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
PROTRIPTYLINE HYDROCHLORIDE
Likely interaction of PROTRIPTYLINE HYDROCHLORIDE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
RABEPRAZOLE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of RABEPRAZOLE. Moderate risk. Avoid
RANITIDINE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of RANITIDINE. Moderate risk. Avoid
RANITIDINE BISMUTH CITRATE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of RANITIDINE BISMUTH CITRATE. Moderate risk. Avoid
REPROTEROL HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of REPROTEROL HYDROCHLORIDE. Moderate risk. Avoid
RIMITEROL HYDROBROMIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of RIMITEROL HYDROBROMIDE. Moderate risk. Avoid
RITODRINE HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of RITODRINE HYDROCHLORIDE. Moderate risk. Avoid
SALBUTAMOL
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of SALBUTAMOL. Moderate risk. Avoid
SALBUTAMOL [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of SALBUTAMOL [INHALED]. Moderate risk. Avoid
SALMETEROL XINAFOATE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of SALMETEROL XINAFOATE. Moderate risk. Avoid
SEMISODIUM VALPROATE
Infrequent reports of SEMISODIUM VALPROATE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
SODIUM VALPROATE
Infrequent reports of SODIUM VALPROATE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
SUCRALFATE
Likely interaction of NEFOPAM HYDROCHLORIDE reducing the ULCER HEALING effect of SUCRALFATE. Moderate risk. Avoid
TERBUTALINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of TERBUTALINE. Moderate risk. Avoid
TERBUTALINE [INHALED]
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of TERBUTALINE [INHALED]. Moderate risk. Avoid
THEOPHYLLINE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of THEOPHYLLINE. Moderate risk. Avoid
TIAGABINE
Infrequent reports of TIAGABINE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
TOPIRAMATE
Infrequent reports of TOPIRAMATE increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
TRANYLCYPROMINE
Theoretical potential for TRANYLCYPROMINE increasing the HYPERTENSIVE effect of NEFOPAM HYDROCHLORIDE. High risk. May need to avoid combination
TRIMIPRAMINE
Likely interaction of TRIMIPRAMINE increasing the ANTIMUSCARINIC side effects of NEFOPAM HYDROCHLORIDE. Moderate risk. May need to avoid combination
TULOBUTEROL HYDROCHLORIDE
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of TULOBUTEROL HYDROCHLORIDE. Moderate risk. Avoid
VALPROIC ACID
Infrequent reports of VALPROIC ACID increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
VIGABATRIN
Infrequent reports of VIGABATRIN increasing the CONVULSANT effect of NEFOPAM HYDROCHLORIDE. Potential risk. Avoid
ZAFIRLUKAST
Infrequent reports of NEFOPAM HYDROCHLORIDE reducing the BRONCHODILATOR effect of ZAFIRLUKAST. Moderate risk. Avoid